Therapeutic Efficacy of Antibiotics in the Treatment of Chronic Diseases

Khwaza, Vuyolwethu; Mbese, Zintle; Aderibigbe, Blessing Atim; Oyedeji, Opeoluwa O.

doi:10.1016/b978-0-12-820054-4.00002-1

Cited by 1 publication

(1 citation statement)

References 176 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Azithromycin is a macrolide antibiotic that is frequently prescribed to treat respiratory bacterial infections and disseminated Mycobacterium avium complex (MAC) infection [170]. Common cold, influenza, and other respiratory viral diseases do not respond to antibiotics such as azithromycin, and their uncontrolled prescription for respiratory illnesses of unknown or viral etiology results in a risk of developing drug-resistant bacterial strains [171].…”

Section: Azithromycinmentioning

confidence: 99%

Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview

et al. 2021

View full text Add to dashboard Cite

Respiratory viruses represent a major public health concern, as they are highly mutated, resulting in new strains emerging with high pathogenicity. Currently, the world is suffering from the newly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is the cause of coronavirus disease 2019 (COVID-19), a mild-to-severe respiratory tract infection with frequent ability to give rise to fatal pneumonia in humans. The overwhelming outbreak of SARS-CoV-2 continues to unfold all over the world, urging scientists to put an end to this global pandemic through biological and pharmaceutical interventions. Currently, there is no specific treatment option that is capable of COVID-19 pandemic eradication, so several repurposed drugs and newly conditionally approved vaccines are in use and heavily applied to control the COVID-19 pandemic. The emergence of new variants of the virus that partially or totally escape from the immune response elicited by the approved vaccines requires continuous monitoring of the emerging variants to update the content of the developed vaccines or modify them totally to match the new variants. Herein, we discuss the potential therapeutic and prophylactic interventions including repurposed drugs and the newly developed/approved vaccines, highlighting the impact of virus evolution on the immune evasion of the virus from currently licensed vaccines for COVID-19.

show abstract

Section: Azithromycinmentioning

confidence: 99%